

NYRx Drug Coverage Overview: Trelegy Ellipta®

December 15, 2025

NYRx Preferred Drug List

The Preferred Drug Program (PDP) promotes the use of less expensive, equally effective drugs within specific drug classes when medically appropriate. Drugs subject to the PDP are listed on the [NYRx Preferred Drug List \(PDL\)](#).

Trelegy Ellipta® is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Trelegy Ellipta® is **non-preferred** and will require a PA. The following alternative agents are [preferred](#) and can be used in combination for your Medicaid members without a PA:

- Arnuity Ellipta® [BLTG](#) (fluticasone furoate)
- Anoro Ellipta® [BLTG](#) (umeclidinium and vilanterol)

Please note, both Arnuity Ellipta® and Anoro Ellipta® are a part of the [NYRx Brand Less Than Generic Program \(BLTG\)](#). The pharmacy should dispense the brand name product and **not** submit a PA request to the provider's office for a generic of a BLTG drug.

What Pharmacy Providers and Prescribers Need to Do

Pharmacy providers and prescribers should become familiar with the [NYRx Preferred Drug Quick List](#) and incorporate this information when deciding what to prescribe for Medicaid members.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Prior Authorization Submission Guide](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.